Product
Jaktinib Hydrochloride
Aliases
Jaktinib, Jaktinib Hydrochloride Cream, Jaktinib Hydrochloride Tablet, Jaktinib Hydrochloride Tablets
11 clinical trials
8 indications
Indication
Atopic DermatitisIndication
Idiopathic Pulmonary FibrosisIndication
MyelofibrosisIndication
Healthy Control ParticipantsIndication
Liver InsufficiencyIndication
Healthy SubjectsIndication
Alopecia AreataIndication
Ankylosing spondylitisClinical trial
A Phase I/II Study Of The Efficacy,Safety and PharmacokineticsOf Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Atopic DermatitisStatus: Completed, Estimated PCD: 2022-09-08
Clinical trial
A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK InhibitorStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary FibrosisStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Phase III Extended Clinical Trial of Long-term Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Study To Evaluate The Pharmacokinetics Of Jaktinib Hydrochloride Tablets In Subjects With Hepatic Impairment And Normal Hepatic FunctionStatus: Completed, Estimated PCD: 2022-09-19
Clinical trial
A Phase II Study To Evaluate The Efficacy And Safety of Jaktinib Hydrochloride Tablets In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib TreatmentStatus: Completed, Estimated PCD: 2022-11-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Adult Patients With Moderate and Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Severe Alopecia Areata.Status: Completed, Estimated PCD: 2021-11-26
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo, Parallel-controlled Phase Ⅱ Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Patients With Active Ankylosing SpondylitisStatus: Completed, Estimated PCD: 2022-08-02
Clinical trial
A Single-dose, Randomized, Open-label, Repeated Cross-over Pharmacokinetic Comparison Study of Two Formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers Under Fasted ConditionsStatus: Completed, Estimated PCD: 2023-12-20